Management of High Disease Activity in Multiple Sclerosis Using Zytux™ (Rituximab, AryoGen Pharmed): Evidence from a Case Report

Abdorreza Naser Moghadasi 1, * and Esmaeil Gheoreyshi Tayeibi 2

1 Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Neurology, Ardabil University of Medical Sciences, Ardabil, Iran

* Corresponding author: Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. Email: abdorrezamoghadasi@gmail.com

Received 2020 January 27; Accepted 2020 April 07.

Abstract

Rituximab is an anti-CD20 monoclonal antibody, which is used for the treatment of various autoimmune diseases. Owing to its marked effect on B cells, rituximab has also been used in the treatment of fulminant multiple sclerosis. The present study aimed to describe the case of a patient with fulminant radiological presentation, which was effectively controlled using rituximab. A 21-year-old woman initially presented with vertigo, which resolved spontaneously. The MRI indicated extensive periventricular involvement with multiple enhancing lesions. The patient was hospitalized and received pulse methylprednisolone (1 g) daily for five days. Afterwards, she was administered with Zytux™ (1 g; rituximab, AryoGen Pharmed) for two weeks.

Keywords: Zytux™, Rituximab, Highly Active Multiple Sclerosis, MRI

1. Introduction

Rituximab is an anti-CD20 monoclonal antibody, which is used for the treatment of various autoimmune diseases (1). Today, rituximab is also applied in the treatment of multiple sclerosis (MS). However, the use of this drug in highly active MS is considered to be challenging and controversial. The present study aimed to describe the case of a patient with a fulminant radiological presentation, which was effectively controlled using Zytux™ (rituximab, AryoGen Pharmed) (2).

2. Case Presentation

A 21-year-old woman initially presented with vertigo in July 2015, which resolved spontaneously. After four months, the patient experienced vertigo and blurred vision in both eyes, which also resolved spontaneously without a physician visit. However, the patient had complaints of loss of balance after three months, for which she referred to a physician. Magnetic resonance imaging (MRI) was requested, which revealed the development of numerous periventricular plaques. The patient underwent pulse therapy and improved markedly. However, she refused to continue the treatment.

Routine laboratory tests (e.g., blood biochemistry) were normal, while the vasculitis tests and anti-aquaporin 4 antibody were negative. The patient had no history of medication use, and her medical history and family history were also unremarkable. The patient was visited in August 2015 with no neurological complaints, and her neurological examination was also intact. The MRI indicated extensive periventricular involvement with multiple enhancing lesions (Figure 1A and 1B). Therefore, she was hospitalized and received pulse methylprednisolone (1 g) daily for five days. Afterwards, the patient was administered with Zytux™ (1 g) for two weeks. In addition, controlled MRI was performed approximately six months after the Zytux™ administration, which showed a significant reduction in the plaque volume, while none of the plaques enhanced (Figure 1C and 1D). Considering the marked improvement, the patient was advised to receive Zytux™ (1 g) every six months. The patient was relapse free and other routine follow ups by MRI were not revealed any new plaque.

3. Discussion

Rituximab is an anti-CD20 monoclonal antibody, which is commonly used for the treatment of various autoimmune diseases (1). Since the role of B cells in the pathogenesis of MS has attracted the attention of researchers, numerous reports have been focused on the
Figure 1. A and B, numerous plaques on T2-weighted images and multiple enhancing lesions after injection; C and D, MRI after 6 months showing reduced volume of plaques with no enhancing lesions.

use of the drug in the treatment of MS, while it is also administered in relapsing-remitting, primary progressive, and secondary progressive MS (1). Moreover, some studies have mentioned the application of rituximab in the case of other concomitant autoimmune diseases than MS (3) or when the patients administered with natalizumab are unable to continue the treatment for any reasons (e.g., high John-Cunningham virus index) (4). Due to the marked effect of the drug on B cells, rituximab has also been used in the treatment of fulminant MS (5).

The treatment of highly active MS is rather challenging (6). Chemotherapy and stem cell therapy have been proposed for the treatment of the cases diagnosed with highly active MS. Despite the controversy over the use of rituximab for the treatment of aggressive or highly active MS (6), some reports have been published in this regard (5).

3.1. Conclusions

The patient described in the present study is an example of the successful treatment of MS using rituximab.

Footnotes

Authors’ Contribution: Abdorreza Naser Moghadasi and Esmaeil Ghoreyshi Tayyebi prepared the text and collected all the medical data, reviewed the literature, provided suitable references, and assisted in the draft version of the paper. Abdorreza Naser Moghadasi reviewed and interpreted
magnetic resonance imaging, collected clinical data, and assisted with preparation of the manuscript. Abdorreza Naser Moghadasi reviewed the paper and revised it to the final format and re-wrote parts of the paper. All authors read and approved the final manuscript.

**Conflict of Interests:** There is no conflict of interest.

**Funding/Support:** There is no funding/support.

**Patient Consent:** The written informed consent of the patient is available upon request.

**References**

1. Salzer J, Svenningsson R, Alping P, Novakova I, Bjorck A, Fink K, et al. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology. 2016;87(20):2074–81. doi: 10.1212/WNL.0000000000003331. [PubMed: 27760868]. [PubMed Central: PMC5109942].

2. Naser Moghadasi A, Darki A, Masoumi P, Hashemi SN, Ghadiri F. Evaluating the efficacy and safety of Zytux(TM) (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: An observational study. Mult Scler Relat Disord. 2019;36:101419. doi: 10.1016/j.msard.2019.101419. [PubMed: 31586800].

3. Berenguer-Ruiz I, Sempere AP, Gimenez-Martinez J, Gabaldon-Torres L, Tahoces L, Sanchez-Perez R, et al. Rescue Therapy Using Rituximab for Multiple Sclerosis. Clin Neuropharmacol. 2016;39(4):178–81. doi: 10.1097/WNF.0000000000000156. [PubMed: 27046661].

4. Alping P, Frisell T, Novakova I, Islam-Jakobsson P, Salzer J, Bjorck A, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol. 2016;79(6):950–8. doi: 10.1002/ana.24651. [PubMed: 27038238].

5. Parfenov V, Du Pasquier R, Schluep M. Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report. Neurologist. 2015;19(6):155–7. doi: 10.1097/NRL.0000000000000030. [PubMed: 26075469].

6. Freedman MS, Rush CA. Severe, Highly Active, or Aggressive Multiple Sclerosis. Continuum (Minneap Minn). 2016;22(3):761-84. doi: 10.1212/CON.0000000000000331. [PubMed: 27266685].